Plasma Protein Characteristics of Long-Term Hemodialysis Survivors

Yao-Ping Lin¹,², Chih-Yu Yang¹,², Chen-Chung Liao³, Wen-Chung Yu², Chin-Wen Chi⁴, Chao-Hsiung Lin³,⁴,⁵,⁶*

¹Institute of Clinical Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ²Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ³Proteomics Research Center, National Yang-Ming University, Taipei, Taiwan, ⁴Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan, ⁵Department of Life Sciences and Institute of Genomic Sciences, National Yang-Ming University, Taipei, Taiwan, ⁶Department of Education and Research, Taipei City Hospital, Taipei, Taiwan

Abstract

Hemodialysis (HD) patients are under recurrent circulatory stress, and hemodialysis has a high mortality rate. The characteristics of plasma proteomes in patients surviving long-term HD remain obscure, as well as the potential biomarkers in predicting prognoses. This study reports the proteome analyses of patient plasma from non-diabetic long-term HD (LHD, dialysis vintage 14.9±4.1 years, n = 6) and the age/sex/uremic etiology-comparable short-term HD (SHD, dialysis vintage 5.3±2.9 years, n = 6) using 2-DE and mass spectrometry. In addition, a 4-year longitudinal follow-up of 60 non-diabetic HD patients was subsequently conducted to analyze the baseline plasma proteins by ELISA in predicting prognosis. Compared to the SHD, the LHD survivors had increased plasma vitamin D binding proteins (DBP) and decreased clusterin, apolipoprotein A-I, haptoglobin, hemopexin, complement factors B and H, and altered isoforms of α1-antitrypsin and fibrinogen gamma. During the 45.7±15 months for follow-up of the 60 HD patient cases, 16 patients died. Kaplan-Meier analysis demonstrated that HD patients with the lowest tertile of the baseline plasma DBP level have a significantly higher mortality rate. Multivariate Cox regression analysis further indicated that DBP is an independent predictor of mortality. In summary, the altered plasma proteins in LHD implicated accelerated atherosclerosis, defective antioxidative activity, increased inflammation/infection, and organ dysfunction. Furthermore, lower baseline plasma DBP in HD patients is related to mortality. The results suggest that the proteomic approach could help discover the potential biomarker in HD prognoses.

Introduction

A global incidence and prevalence of end-stage renal disease (ESRD) patients requiring maintenance dialysis has been on the rise [1]. Although hemodialysis (HD) is a major treatment modality to maintain their lives, these patients are under recurrent circulatory stress caused by intermittent dialysis sessions [2]. In addition, ESRD patients still have substantially reduced life expectancy, mostly because of cardiovascular disease [3].

For ease of obtaining research specimens, plasma has the advantage over cells or tissue because it can be collected in a relatively non-invasive manner. Moreover, all the protein components are readily accessible in a single compartment without requiring additional extraction procedures. Advances in proteomic techniques have facilitated the investigation of global changes in human plasma proteomes. Because of their pivotal clinical implications, intensive efforts and large-scale collaborative studies have been devoted to compiling human plasma proteomes for further integrated studies [4]. Applications of plasma proteome analysis are emerging in studies on cancer [5] and cardiovascular [6] and infectious diseases [7]. In HD patients, Chu et al. focused on the identification of toxins that accumulate in the uremic sera [8]. Langlois et al. aimed to clarify differences in the serum proteome between HD patients and healthy participants [9]. Weissinger et al. studied the effects of oral vitamin C supplementation on plasma polypeptide profiles in HD patients by CE-ESI-TOF MS [10]. Profiling plasma proteome in patients surviving long-term HD (LHD) and identifying potential biomarkers for prognoses is worthy of investigation.

The present study hypothesizes that plasma proteomes of LHD survivors might be different from those who received short-term HD (SHD). In addition, certain protective or beneficial markers might be evolved to reflect the dialysis-related circulatory stress. To address this issue, we conducted a 2-DE-based comparison of the plasma proteomes of ESRD patients receiving different maintenance HD vintage. Subsequently, the differentially expressed proteins were identified by MALDI-TOF mass spectrometry. Specifically, the plasma level of a potential protein marker, vitamin D binding protein (DBP), was measured using ELISA in another 60 HD patients to characterize the clinical significance of DBP during a 4-year prospective follow-up. Our study on plasma protein profiles in HD patients with different dialysis vintage might act as a reference for mining potential biomarkers for prognoses.
Materials and Methods

Human Subjects

Each patient gave written informed consent, and the study protocol was approved by the Institutional Review Board of Taipei Veterans General Hospital. Non-diabetic ESRD patients under maintenance HD were enrolled in the present study if they met the following criteria: (1) had undergone maintenance HD for more than 6 months, (2) had no recent cerebrovascular or cardiovascular events, and (3) had no symptoms or signs of concurrent infection, active autoimmune/collagen vascular disease, liver dysfunction, or malignancy. For a comparison of plasma proteomes, we enrolled long-term non-diabetic HD (dialysis vintage 14.9 ± 4.1 years, n = 6) patients and the age/sex/uremic etiology comparable short-term HD (dialysis vintage 5.3 ± 2.9 years, n = 6). To determine the clinical significance of our identified proteins, another 60 prevalent non-diabetic HD patients were further enrolled for prospective follow-up.

HD was prescribed as 4-h dialysis sessions 3 ± 6 weekly using 1.8-m² surface area dialyzers with bicarbonate-based dialysate (\(\text{HCO}_3^- 39 \text{ mEq/L, } \text{Na}^+ 140 \text{ mEq/L, } \text{K}^+ 2.0 \text{ mEq/L, } \text{Ca}^{2+} 3- \text{mEq/L and } \text{Mg}^{2+} 1 \text{ mEq/L})\). All patients received subcutaneous

| Table 1. Demographics and biochemistry of the studied HD population. |
|---------------------|---------------------|---------------------|
| Screening subjects  |                      |                      |
| Age, years          | 68.4 ± 15.2          | 60.0 ± 17.1          | 0.250 |
| Gender, female/male | 4/2                 | 4/2                 |       |
| Dialysis vintage, years | 5.3 ± 2.9           | 14.9 ± 4.1          | 0.001 |
| Etiology            |                      |                      |
| Chronic glomerulonephritis | 3           | 3                   |       |
| Chronic interstitial nephritis | 3      | 3                   |       |
| Body weight, kg     | 55.1 ± 7.8           | 52.6 ± 5.8           | 0.540 |
| Height, cm          | 156.7 ± 10.0         | 157.0 ± 7.2          | 0.948 |
| Body mass index, kg/m² | 21.6 ± 2.9         | 20.3 ± 1.8           | 0.359 |
| Systolic blood pressure, mmHg | 145.3 ± 11.7 | 141.0 ± 16.1 | 0.609 |
| Diastolic blood pressure, mmHg | 80.3 ± 6.2   | 77.1 ± 4.9           | 0.347 |
| Blood chemistry     |                      |                      |
| Leukocyte count, \(\times 10^3/\text{µL}\) | 6.303 ± 1.725 | 5.688 ± 1.258 | 0.496 |
| Hemoglobin, g/dL    | 11.1 ± 2.1           | 10.1 ± 1.9           | 0.425 |
| Hematocrit, %       | 34.9 ± 7.5           | 31.8 ± 5.6           | 0.432 |
| Albumin, g/dL       | 4.1 ± 0.2            | 4.3 ± 0.3            | 0.351 |
| Blood urea nitrogen, mg/dL | 84.2 ± 10.3 | 92.9 ± 6.8 | 0.113 |
| Creatinine, mg/dL   | 10.8 ± 1.9           | 12.1 ± 1.3           | 0.202 |
| Sodium, meq/dL      | 141.5 ± 1.8          | 142.0 ± 2.2          | 0.674 |
| Potassium, meq/dL   | 5.1 ± 0.6            | 5.0 ± 0.8            | 0.875 |
| Fasting blood sugar, mg/dL | 99.7 ± 6.6 | 98.1 ± 16.3 | 0.827 |
| Cholesterol, mg/dL  | 171.1 ± 40.5         | 195.1 ± 43.7         | 0.347 |
| HDL-C, mg/dL        | 55.5 ± 31.6          | 51.7 ± 14.7          | 0.793 |
| LDL-C, mg/dL        | 129.7 ± 54.6         | 129.0 ± 36.6         | 0.981 |
| ApoB, mg/dL         | 106.3 ± 41.9         | 104.3 ± 24.3         | 0.922 |
| Lp(a), mg/dL        | 8.1 ± 4.3            | 12.3 ± 8.8           | 0.594 |
| Triglyceride, mg/dL | 149.6 ± 47.5         | 147.4 ± 75.3         | 0.955 |
| Uric acid, mg/dL    | 8.9 ± 1.2            | 9.4 ± 1.4            | 0.505 |
| Alanine aminotransferase, U/L | 19.1 ± 5.7  | 23.3 ± 5.0 | 0.200 |
| γ-glutamyl transferase, U/L | 31.1 ± 29.5 | 14.6 ± 5.2 | 0.207 |
| Alkaline phosphatase, U/L | 88.5 ± 28.5 | 127.8 ± 50.1 | 0.125 |
| Calcium, mg/dL      | 9.5 ± 0.9            | 9.6 ± 0.8            | 0.675 |
| Phosphate, mg/dL    | 5.3 ± 0.7            | 5.6 ± 1.4            | 0.643 |
| Intact-parathyroid hormone, pg/mL | 269.7 ± 295.3 | 315.2 ± 264.4 | 0.553 |
| 25(OH) Vitamin D, ng/mL | 16.6 ± 5.5 | 16.9 ± 4.6 | 0.916 |
| Kt/V                | 1.7 ± 0.2            | 1.7 ± 0.1            | 0.982 |

doi:10.1371/journal.pone.0040232.t001
recombinant erythropoietin at a mean dosage of 20 000 units monthly to maintain a hematocrit level of 30%, according to the guidelines set by the National Health Insurance Bureau of Taiwan. Vitamin D supplements and statin were prescribed according to the Kidney Disease Outcome Quality Initiative (KDOQI) clinical practice guidelines. The efficacy (adequacy) of HD was indexed by the clearance index Kt/V [11]. Adherence to diet was assessed by serum K⁺, PO₄³⁻, and albumin [12].

Preparation of Plasma Samples

All plasma samples were collected on a mid-week non-dialysis day to avoid possible acute generation or clearance of proteins by the dialysis procedure. The patients’ blood was drawn in EDTA-tubes (BD, Franklin Lakes, NJ, USA) and immediately centrifuged at 3000 rpm at 4°C for 15 min. The plasma were thereafter divided into aliquots and stored at −80°C. Samples were centrifuged after thawing without visible fibrinogen precipitation, and subjected to subsequent 2D and ELISA analyses.

Two-dimensional Gel Electrophoresis (2-DE)

The 2-DE analyses of the collected plasma were performed individually. Before electrophoresis, all plasma samples were carefully inspected to ensure that no hemolysis was present, which might have affected the analysis results. Protein concentration was determined using the PlusOne 2-D Quant Kit (GE Healthcare, Piscataway, NJ, USA), according to the manufacturer’s manual. To detect the less abundant proteins present in the plasma, Qproteome Albumin/IgG Depletion Kits (Qiagen, Hilden, Germany) were used as a prefractionation step to remove abundant human albumin and immunoglobulins with similar efficiency among samples. The 2-DE was performed using an IPGphor IEF system (GE Healthcare, Piscataway, NJ, USA) and a PROTEAN Ixi Cell electrophoresis unit (Bio-Rad, Hercules, CA, USA). Plasma protein was first dissolved in a lysis buffer containing 7 M urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, and 2 mM triphenylphosphine. Thereafter, approximately 120 μg of protein was loaded into 18 cm, linear pH 3–10 Immobiline DryStrips (GE Health Care, Uppsala, Sweden) for in-gel rehydration. Isoelectric focusing was conducted using the following program: 0 V × 3.5 h; 50 V × 3.5 h; 200 V × 1 h; 500 V × 1 h; 1000 V × 1 h. The gradient was raised from 1000 V to 8000 V within 30 min, and the focusing was terminated after 70 000 Vh. After isoelectric focusing, the IPG strips were equilibrated in an equilibrium buffer (50 mM Tris-HCl (pH 8.8), 6 M urea, 2% w/v SDS, 30% v/v glycerol, and 1% w/v dithiothreitol) for 15 min, and then soaked in the same buffer containing 2.5% w/v iodoacetamide for another 15 min. The strips were then placed on a 12% SDS-PAGE gel and immobilized with agarose sealing solution (0.5% w/v agarose, 25 mM Tris, 192 mM glycine, 0.1% w/v SDS, and a trace of bromophenol blue). SDS-PAGE was performed with this strip, and the resulting gel was subsequently fixed in the buffer (40% v/v methanol, 10% v/v acetic acid) for 30 min. The fixed gel was then incubated in 30% methanol for 15 min, washed by Milli-Q water, and placed in 0.05% w/v sodium thiosulphate for 2 min. After washing with Milli-Q water, gels were incubated in 0.2% silver nitrate for 25 min. The gels were then washed quickly and developed with 3% w/v sodium carbonate, 0.001% w/v sodium thiosulphate, and 0.02% formaldehyde, until the desired spot profiles were obtained. Development was stopped by 1.4% EDTA. Gel images were obtained using a flatbed scanner and were quantitatively analyzed by PDQuest v7.2 software (Bio-Rad, Hercules, CA, USA) for the MWs, pIs, and relative intensities of all protein spots.
the criterion for the signal-to-noise ratio was set to 4. Each recorded mass spectrum was further analyzed by the MASCOT program (http://www.matrixscience.com) by searching the NCBI nr database with the following settings: digested enzyme, trypsin; missed cleavage site, one; variable modification: carbamidomethylation (Cysteine) and oxidation (Methionine, Histidine and Tryptophan); peptide tolerance, less than 150 ppm and mass values, MH monoisotopic. Only proteins with MOWSE scores above the criterion for the signal-to-noise ratio were chosen.

For those spots that could not be identified by MALDI-TOF, further sequencing of peptide amino acids was performed using LC-MS/MS (QTOF-2 from Micromass, Manchester, UK). Briefly, tryptic peptides were separated on a reversed-phase C18 capillary column then delivered into to the electrospray source of mass spectrometer. The MS was operated in positive ion mode with source temperature at 80°C and cone voltage set to 45 V. A voltage of 3.2 kV was applied to the source capillary. Resulting MS/MS spectra were recorded in the data-dependent acquisition mode whereby the four most abundant doubly or triply-charged ions were selected for collision-induced dissociation of which collision energies were set to 10 and 30 V for MS and MS/MS scans respectively. Mass spectra were processed using the MassLynx 4.0 software (Micromass) and the protein identities were analyzed using the MS/MS peak lists generated from MassLynx. Protein identification was carried out by interpreting MS/MS data based on NCBI nr gene database with the following parameters: taxonomy: Homo sapiens; digested enzyme: trypsin; missed cleavage site: one; variable modification: carbamidomethylation (cysteine) and oxidation (methionine); peptide mass tolerance: 1 Da; MS/MS tolerance: 0.6 Da; charge of 2/3; and monoisotopic mass and peptide charge of 2/3 were chosen.

### Enzyme Linked Immunosorbent Assay (ELISA)

The blood concentrations of human DBP and clusterin were measured using ELISA kits (Immun Diagnostik, Bensheim, Germany; BioVendor Laboratory Medicine Inc., Brno, Czech Republic), with a sensitivity of 0–60 ng/mL and 0–640 U, respectively. All reagents, samples, and working standards were prepared according to the manufacturer’s instruction. Each measurement was performed in duplicate. In brief, a 100 μL assay dilution buffer was added to each well prior to the addition of the standard or sample in the capture antibody-coating microplate. Thereafter, 100 μL of samples, standard or control, were incubated at room temperature for 1 h with horizontal shaking. Unbound residue was washed off by a 350 L wash buffer for 4 times; subsequently, 100 μL of HRP-conjugated antibody was added, and the mixture was incubated for 1 h. After 4 more washes with the buffer, a 100 μL premixed enhanced luminal and hydrogen peroxide substrate was added and incubated for 10 min to 20 min at ambient temperature. The relative light units of each sample reaction were then read within 30 min by an automated reader. Sample concentrations were calculated using the machine program by comparing with a best-fit 4-parameter logistic standard curve.

### Statistics

SPSS 15.0 was used for statistical analysis. Continuous data were expressed as mean ± standard deviation (SD). Comparisons

| Spot No. | Protein names         | Theoretical Mr (kDa)/pl | Observed Mr (kDa)/pl | Identification method* | Sequence coverage | MASCOT score | Fold changes |
|----------|-----------------------|-------------------------|----------------------|------------------------|------------------|--------------|--------------|
| 1        | Haptoglobin           | 38/6.27                 | 44/4.74              | sequencing             | 37               | 617          | ↓ 2.6±0.8    |
| 2        | Haptoglobin           | 38/6.27                 | 43/5.04              | pmf                    | 22               | 79           | ↓ 4.3±1.4    |
| 3        | Haptoglobin           | 38/6.27                 | 42/5.32              | sequencing             | 24               | 337          | ↓ 3.9±1.5    |
| 4        | Haptoglobin           | 38/6.27                 | 42/5.50              | sequencing             | 27               | 349          | ↓ 2.0±0.5    |
| 5        | Haptoglobin           | 38/6.27                 | 38/5.90              | pmf                    | 17               | 47           | ↓ 2.9±0.4    |
| 6        | Clusterin             | 52/6.06                 | 37/4.92              | sequencing             | 6                | 97           | ↓ 1.9±0.4    |
| 7        | Clusterin             | 52/6.06                 | 38/4.84              | sequencing             | 6                | 86           | ↓ 1.8±0.3    |
| 8        | Clusterin             | 52/6.06                 | 35/5.08              | sequencing             | 4                | 59           | ↓ 3.1±0.1    |
| 9        | Complement factor H   | 51/6.77                 | 60/6.32              | sequencing             | 10               | 180          | ↓ 2.0±0.4    |
| 10       | Complement factor B   | 85/6.55                 | 102/6.17             | sequencing             | 12               | 68           | ↓ 2.5±1.0    |
| 11       | α1-antitrypsin        | 44/5.37                 | 51/4.93              | pmf                    | 21               | 87           | ↓ 2.8±0.4    |
| 12       | α1-antitrypsin        | 44/5.37                 | 51/4.86              | pmf                    | 28               | 96           | ↓ 2.3±0.8    |
| 13       | Apolipoprotein A-IV   | 28/5.39                 | 22/5.11              | pmf                    | 41               | 130          | ↓ 3.2±0.8    |
| 14       | Hemopexin precursor   | 51/6.55                 | 80/5.69              | pmf                    | 18               | 69           | ↓ 2.2±0.1    |
| 15       | α1-antitrypsin        | 44/5.37                 | 25/4.56              | pmf                    | 17               | 56           | ↓ 3.6±1.4    |
| 16       | α1-antitrypsin        | 44/5.37                 | 59/5.02              | pmf                    | 35               | 89           | ↓ 2.6±0.8    |
| 17       | Vitamin D binding protein | 53/5.40             | 57/5.18              | sequencing             | 19               | 313          | ↓ 2.8±1.0    |
| 18       | Vitamin D binding protein | 53/5.33             | 58/5.27              | pmf                    | 30               | 133          | ↑ 5.2±0.7    |
| 19       | Vitamin D binding protein | 53/5.33             | 57/5.25              | pmf                    | 47               | 140          | ↑ 2.3±0.5    |
| 20       | Fibrinogen gamma chain | 49/5.61              | 50/5.61              | pmf                    | 21               | 108          | ↑ 1.9±0.2    |
| 21       | Fibrinogen gamma chain | 52/5.37              | 50/5.61              | pmf                    | 36               | 134          | ↑ 2.1±0.4    |

*Protein identification was done by the peptide mass fingerprinting (pmf) using MALDI-TOF MS, or by sequencing amino acids using Q-TOF tandem MS, as shown in the supplementary materials including Figure S1 and Data S1.

doi:10.1371/journal.pone.0040232.t002
between different groups were analyzed by the Student’s t test for continuous variables or χ² test for categorical variables. Kaplan-Meier analysis was used to compare the mortality rate related to the tertile of the DBP protein level. The Cox proportional hazards model was used to investigate significant factors for determining mortality. Factors related to mortality under univariate Cox regression analysis with p-values less than 0.10 were entered for further multivariate Cox regression analysis. A p-value of less than 0.05 was considered statistically significant.

Results

The demographic and biochemical data of the participating HD patients are summarized in Table 1. Except for the dialysis vintage, the backgrounds of the SHD and LHD patients were similar for age, sex, and anthropometrical indices such as height, weight and body mass index, blood pressure, lipid profile, calcium, phosphate, and the dialysis adequacy index Kt/V.

Patient plasma samples were analyzed by 2-DE over a pH ranged between 3 and 10 to obtain optimal resolution and protein separation. An average of 598±116 spots in each silver-stained gel was visualized and subsequently quantified using PDQuest software (Bio-Rad). After deliberate inspection of each gel image and comparative analysis, a consistent trend of 2 increased spots ($≥1.5$ folds) and 19 decreased spots ($≤1.5$ folds) were observed in the LHD patients, compared to those of the other 6 age- and sex-comparable SHD counterparts. The locations of the differential spots are indicated with numbers in a representative gel of LHD patient plasma (Fig. 1).

Protein spots with greater than 1.5-fold intensity change upon HD duration were excised, trypsin-digested, and determined by mass spectrometry. Table 2 shows a summary of the protein identification results. The sequence coverage of the identified proteins ranges from 4% to 47%, depending on the protein size and quantity. The enlarged gel sections displayed in Fig. 2 show the expression patterns of plasma proteins, including clusterin, apolipoprotein A-IV, haptoglobin, hemopexin, complement factor B, complement factor H, DBP, α1-antitrypsin, and fibrinogen γ, in the representative SHD and LHD patients. In each bar representation, the intensities of the squared spots were quantitatively analyzed using PDQuest software (Fig. 2). In the plasma of LHD patients, we observed the presence of increased DBP protein, as well as downregulation of a number of proteins, including clusterin, apolipoprotein A-IV, haptoglobin, hemopexin, complement factor B, and complement factor H, compared with those of the SHD counterparts. In addition, the isoform profiles of α1-antitrypsin and fibrinogen γ were altered, as shown in Fig. 2.

Among the identified proteins, we further used ELISA to validate the plasma concentrations of DBP and clusterin in the same patients’ plasma analyzed by 2-DE. Concordant with the 2-DE expression patterns, the LHD patients (n = 6, Group II in Table 1) have significantly higher DBP levels (204.5±63.9 mg/L vs 149.0±71.6 mg/L, p = 0.036) and lower clusterin (282.3±105.8 mg/L vs 438.5±174.2 mg/L, p = 0.011) than SHD patients (n = 6, Group I in Table 1) (Fig. 3).

To explore the clinical implication of plasma levels of DBP in HD patients, we followed up another 60 prevalent HD patients based on their initial plasma DBP detected by ELISA. During the follow-up of 45.7±15.9 months, 16 patients died (10 acute coronary events and 6 heart failures). The baseline plasma ELISA data of the dead patients (n = 16) disclosed their lower DBP compared to the surviving patients (n = 44) (165.6±59.6 vs 214.7±60.8 mg/L, p = 0.007). No significant differences existed for HD duration, age, sex, anthropometrical indices, blood pressure, lipid profile, calcium, phosphate, and Kt/V between the dead and living patients (Table 3).

Kaplan-Meier analysis demonstrated that HD patients with the lowest tertile of baseline plasma DBP level have a significantly
higher mortality rate compared to patients with the top tertile level ($p = 0.030$; log-rank test) (Fig 4). In addition, initial univariate Cox regression analysis of factors significantly associated with mortality ($p<0.1$) disclosed that older age, lower plasma DBP, hypoalbuminemia, and decreased uremic solute clearance (as indexed by Laboratory data

Table 3. Comparison between the surviving and deceased HD patients in a four-year follow-up.

|                         | Survivors n = 44* | Deceased n = 16* | P     |
|-------------------------|-------------------|------------------|-------|
| ELISA - Vitamin D binding protein, mg/L | 214.7 ± 60.8 | 165.6 ± 59.6 | 0.007 |
| Age, years              | 58.2 ± 14.5       | 67.8 ± 12.5     | 0.021 |
| Gender, male %          | 35                | 44               | 0.530 |
| Dialysis vintage, years | 7.9 ± 5.5         | 5.9 ± 4.2       | 0.158 |
| **Etiology**            |                   |                  |       |
| Chronic glomerulonephritis | 32               | 11              |       |
| Chronic interstitial nephritis | 5                | 2               |       |
| Hypertensive nephrosclerosis | 4               | 2               |       |
| Lupus nephritis         | 3                 | 1               |       |
| **Body weight, Kg**     | 53.4 ± 7.9        | 56.8 ± 8.8      | 0.273 |
| **Height, cm**          | 157.2 ± 7.9       | 160.6 ± 8.7     | 0.157 |
| **Body mass index, Kg/m²** | 21.2 ± 2.8      | 21.9 ± 2.9      | 0.365 |
| Systolic blood pressure, mmHg | 141.8 ± 14.4 | 145.4 ± 16.7    | 0.422 |
| Diastolic blood pressure, mmHg | 79.1 ± 6.9  | 79.5 ± 9.2      | 0.850 |
| **Laboratory data**     |                   |                  |       |
| Leukocyte count, $\times 10^3/\muL$ | 6.231 ± 1.345 | 5.696 ± 1.180  | 0.163 |
| Hemoglobin, g/dL        | 11.8 ± 1.9        | 11.2 ± 1.7      | 0.517 |
| Hematocrit, %           | 31.8 ± 3.2        | 31.8 ± 5.9      | 0.994 |
| Albumin, g/dL           | 4.2 ± 0.2         | 4.1 ± 0.3       | 0.113 |
| Blood urea nitrogen, mg/dL | 90.8 ± 15.4     | 92.7 ± 17.2     | 0.683 |
| Creatinine, mg/dL       | 10.6 ± 1.8        | 10.3 ± 1.6      | 0.843 |
| Sodium, meq/dL          | 140.6 ± 2.4       | 140.6 ± 2.2     | 0.983 |
| Potassium, meq/dL       | 5.1 ± 0.7         | 5.3 ± 0.7       | 0.303 |
| Fasting blood sugar, mg/dL | 103.6 ± 18.8    | 110.8 ± 17.6    | 0.189 |
| Cholesterol, mg/dL      | 177.3 ± 36.4      | 173.5 ± 35.6    | 0.717 |
| HDL-C, mg/dL            | 54.8 ± 20.9       | 55.4 ± 16.1     | 0.921 |
| LDL-C, mg/dL            | 125.1 ± 45.5      | 109.5 ± 54.8    | 0.309 |
| ApoB, mg/dL             | 102.7 ± 30.7      | 90.4 ± 38.1     | 0.243 |
| Lp(a), mg/dL            | 8.1 ± 8.7         | 10.2 ± 9.2      | 0.457 |
| Triglyceride, mg/dL     | 154.7 ± 85.5      | 177.3 ± 157     | 0.523 |
| Uric acid, mg/dL        | 8.7 ± 14.1        | 8.3 ± 13        | 0.255 |
| Alanine aminotransferase, U/L | 19.5 ± 14.4    | 23.2 ± 11.1     | 0.360 |
| γ-glutamyl transferase, U/L | 26.6 ± 24.2    | 26.5 ± 22.3     | 0.992 |
| Alkaline phosphatase, U/L | 112.4 ± 55.1  | 139.1 ± 71.9    | 0.128 |
| Calcium, mg/dL          | 9.4 ± 0.9         | 9.2 ± 0.8       | 0.153 |
| Phosphate, mg/dL        | 5.5 ± 1.3         | 5.8 ± 1.3       | 0.458 |
| Calcium × Phosphate product, mg²/dL² | 53.2 ± 12.2  | 53.6 ± 14.5     | 0.932 |
| Intact-parathyroid hormone, pg/mL | 268.5 ± 294.1 | 360.3 ± 231.3  | 0.285 |
| 25(OH) Vitamin D, ng/mL | 16.9 ± 7.7        | 19.0 ± 7.8      | 0.388 |
| Kt/V                    | 1.69 ± 0.17       | 1.63 ± 0.22     | 0.397 |

*Values are expressed as mean ± SD or percent unless otherwise listed.

Published: July 2012 | Volume 7 | Issue 7 | e40232

Discussion

Chronic HD patients are under constant exposure to uremic toxins and hemodynamic stress caused by fluctuations in blood pressure and fluid status. HD patients who can survive long and remain in stable conditions might be likened to centenarians in the general population. We are curious as to whether their plasma proteomes are altered, or whether certain protective factors might exist to endure the prolonged deleterious uremic milieu. By harnessing the power of 2-DE-based comparative proteomic techniques, we profiled plasma protein changes in HD patients with different dialysis vintages and identified 9 differentially expressed proteins in the current study’s LHD survivors. These protein profiles include increased DBP and decreased clusterin, apolipoprotein A-I, haptoglobin, hemopexin, complement factors B and H, and altered isoform profiles of α1-antitrypsin and fibrinogen γ. We speculated that these protein changes might be related to intricate influences caused by adsorption [13] or elimination [14] of proteins by HD procedure, that is, altered catabolism resultant from deranged enzyme activities in the uremic state, and post-translational modifications by increased oxidative [15] and carbonyl stress [16] throughout the disease process.

By binding vitamin D, DBP is well recognized for regulating calcium-phosphate homeostasis [17] and exerting great impacts on cardiovascular calcifications [18]. It has been noted that, in addition to transporting vitamin D and its metabolites, DBP plays crucial roles in inflammation and immune reactions by mediating chemotaxis [19] and macrophage activation [20]. Moreover, DBP constitutes an important extracellular actin-scavenger system that eliminates actin released from cell lysis [21]. Without clearance, these accumulated extracellular actin filaments are extremely
Table 4. Cox proportional hazard model for prognosis of HD patients at a four-year follow-up.

| Factor                        | Univariate* |          |          | p Value | Multivariate* |          |          | p Value |
|-------------------------------|-------------|----------|----------|---------|---------------|----------|----------|---------|
|                               | HR          | Lower    | Upper    |         | HR            | Lower    | Upper    |         |
| ELISA - Vitamin D binding protein, 10 mg/L | 0.895 | 0.817 | 0.980 | 0.013* | 0.756 | 0.951 | 0.006 |
| Age, year                     | 1.045 | 1.003 | 1.089 | 0.037* | 1.005 | 1.092 | 0.027 |
| Male gender, %                | 1.445 | 0.538 | 3.883 | 0.465  |                |          |          |         |
| Dialysis vintage, years       | 0.900 | 0.800 | 1.013 | 0.080* |                |          |          |         |
| Body weight, Kg               | 1.046 | 0.986 | 1.109 | 0.137  |                |          |          |         |
| Height, cm                    | 1.048 | 0.987 | 1.113 | 0.129  |                |          |          |         |
| Body mass index, kg/m²        | 1.040 | 0.889 | 1.217 | 0.620  |                |          |          |         |
| Systolic blood pressure, mmHg | 1.011 | 0.978 | 1.045 | 0.514  |                |          |          |         |
| Diastolic blood pressure, mmHg| 1.008 | 0.942 | 1.079 | 0.823  |                |          |          |         |
| Smoking index                 | 1.167 | 0.795 | 1.712 | 0.430  |                |          |          |         |
| Medications                   |            |          |          |         |                |          |          |         |
| ACE inhibitor/ARB, %          | 1.132 | 0.403 | 3.183 | 0.936  |                |          |          |         |
| Vitamin D₃, %                 | 1.079 | 0.347 | 3.533 | 0.895  |                |          |          |         |
| Laboratory data               |            |          |          |         |                |          |          |         |
| Leukocyte count, x 10⁴/μL     | 1.000 | 0.999 | 1.000 | 0.117  |                |          |          |         |
| Hemoglobin, g/dL              | 1.011 | 0.684 | 1.495 | 0.954  |                |          |          |         |
| Hematocrit, %                 | 1.012 | 0.887 | 1.154 | 0.863  |                |          |          |         |
| Albumin, g/dL                 | 0.162 | 0.020 | 1.328 | 0.090* | 0.064 | 0.574 | 0.012 |
| Blood urea nitrogen, mg/dL    | 1.005 | 0.973 | 1.038 | 0.752  |                |          |          |         |
| Creatinine, mg/dL             | 1.134 | 0.648 | 1.983 | 0.660  |                |          |          |         |
| Sodium, meq/dL                | 1.023 | 0.835 | 1.254 | 0.826  |                |          |          |         |
| Potassium, meq/dL             | 1.464 | 0.721 | 2.973 | 0.291  |                |          |          |         |
| Fasting blood sugar, mg/dL    | 1.016 | 0.990 | 1.042 | 0.226  |                |          |          |         |
| Total cholesterol, mg/dL      | 0.998 | 0.985 | 1.012 | 0.777  |                |          |          |         |
| HDL-C, mg/dL                  | 1.001 | 0.972 | 1.032 | 0.939  |                |          |          |         |
| LDL-C, mg/dL                  | 0.992 | 0.980 | 1.004 | 0.210  |                |          |          |         |
| ApoB, mg/dL                   | 0.985 | 0.966 | 1.005 | 0.147  |                |          |          |         |
| Lp(a), mg/dL                  | 1.005 | 0.947 | 1.067 | 0.875  |                |          |          |         |
| Triglycerides, mg/dL          | 1.001 | 0.997 | 1.005 | 0.557  |                |          |          |         |
| Uric acid, mg/dL              | 0.821 | 0.576 | 1.170 | 0.275  |                |          |          |         |
| Alanine aminotransferase, U/L | 1.008 | 0.982 | 1.036 | 0.542  |                |          |          |         |
| γ-glutamyl transferase, U/L   | 0.999 | 0.982 | 1.017 | 0.906  |                |          |          |         |
| Alkaline phosphatase, U/L     | 1.004 | 0.997 | 1.011 | 0.231  |                |          |          |         |
| Calcium, mg/dL                | 0.591 | 0.332 | 1.052 | 0.074* |                |          |          |         |
| Phosphate, mg/dL              | 1.162 | 0.789 | 1.713 | 0.447  |                |          |          |         |
| Calcium × Phosphate product    | 1.003 | 0.964 | 1.044 | 0.876  |                |          |          |         |
| Intact-parathyroid hormone, pg/mL | 1.001 | 1.000 | 1.003 | 0.157  |                |          |          |         |
| 25(OH) Vitamin D, ng/mL       | 1.033 | 0.973 | 1.096 | 0.289  |                |          |          |         |
| Kt/V                          | 0.026 | 0.002 | 0.545 | 0.124  |                |          |          |         |

*aValues are expressed as mean ± SD or percent.

bACE, angiotensin converting enzyme; ARB, angiotensin receptor blocker.

*cCI, confidence interval.

dHR, hazard ratio.

*p<0.10 in univariate Cox regression analysis.

doi:10.1371/journal.pone.0040232.t004

Plasma Proteomics in Hemodialysis

---

detrimental because of microvasculature blockage, and consequently leads to organ dysfunction. Decreased plasma DBP has also been reported to affect patient prognoses in multiple organ failure [22], and to fulminant hepatic failure [23]. Because of our observations of higher DBP levels in long-term surviving HD patients, and because lower DBP is related to increased risk of
4-year mortality, we reasoned that DBP might exert protective effects on HD.

Clusterin is a highly conserved and ubiquitously expressed secretory glycoprotein that regulates lipid transport and local deposition. Augmented clusterin expression has been demonstrated in human atherosclerotic lesions [24] and in endothelial cell cultures exposed to laminar shear stress [25]. An elevated serum clusterin level was observed in patients with coronary artery disease and myocardial infarction [26]. Therefore, clusterin was proposed to be an index of underlying cardiovascular damage. Clusterin is also a senescence biomarker that is upregulated during replicative and stress-induced premature senescence [27]. It could interact with stress-induced extracellular amyloid aggregations [28]. Our observation of lower plasma clusterin expressed in LHD survivors implies that these specific patients might develop certain protective mechanisms to resist hemodynamics and uremic stress with less accumulated damages during the course of HD.

We found that the current study's LHD patients remained not refrained from injuries imposed by the uremic milieu. Their plasma revealed downregulation of certain cardiovascular-protective proteins such as apolipoprotein A-IV, haptoglobin, and hemopexin, which could explain the accelerated atherosclerosis process accompanying HD [29]. Apolipoprotein A-IV is an anti-atherogenic factor that participates in the reverse transport of cholesterol from peripheral cells to the liver and other steroidogenic organs, and acts as a potent inhibitor of lipid oxidation [30]. Decreased plasma apolipoprotein A-IV has also been demonstrated in patients with coronary artery disease [31]. Both haptoglobin and hemopexin are heme-binding glycoproteins that protect the body from hemo globin-induced oxidative damage, nitric oxide toxicity, and pro-inflammatory effects induced by intravascular hemolysis. Haptoglobin also functions as a chaperone that inhibits oxidation-induced misfolding of extracellular proteins, and thus, exerts anti-inflammatory effects. In addition to binding heme, hemopexin could suppress neutrophil adhesion and phagocytosis. We believe that the downregulation of haptoglobin and hemopexin might reflect an exhausted antioxidant reserve in LHD patients while counteracting the persistent deranged redox state and inflammatory stresses.

Repetitive contact of blood with HD devices could activate the complement system and contribute to the lower level of complement factors B and H in the current study's LHD patients [32]. The complement system is the main mediator of innate immunity and contributes to the recognition, opsonization, and lysis of microorganisms. Therefore, HD patients with decreased factors B and H are immunocompromised, susceptible to bacterial infections, and in a state of chronic inflammation [33].

Altered isoform patterns of plasma α1-antitrypsin and fibrinogen γ were demonstrated in the study's HD patients with different dialysis vintages. α1-Antitrypsin is a potent inhibitor of several proteolytic enzymes that inhibit neutrophil superoxide production [34]. α1-Antitrypsin is related to the atherogenesis process, and different genotypes/phenotypes were related to diverse ischemic cerebrovascular and cardiovascular disease risks. Furthermore, serum α1-antitrypsin has been reported to be an important index of chronic inflammation in HD patients [35]. Exogenous administration of α1-antitrypsin could confer protection against ischemic/reperfusion injury [36]. Because HD is an ischemia-reperfusion process, α1-antitrypsin might serve as another therapeutic target.

Fibrinogen, the precursor of fibrin, is a 6-chain protein comprising 2 sets of the 3 polypeptide chains α, β, and γ. The γ chain interacts with other fibrinogen molecules, coagulation factors, growth factors, and integrins. Therefore, fibrinogen γ prominently participates in platelet aggregation, coagulation, clot retraction, thrombosis, and inflammation [37]. The differential expression patterns of plasma α1-antitrypsin and fibrinogen γ chain isoforms have also been observed in other diseases. Mateos-Caceres et al. reported the differential expression of α1-antitrypsin and fibrinogen γ chain isoforms between the plasma of acute myocardial infarction and unstable angina patients [38]. We believe that these isoforms might reflect the disparate host responses to diverse pathological processes of HD and they merit further investigation.

High performance HD or more prolonged HD were expected to cause more efficient removal of uremic toxins. However, it might concurrently lead to the loss of plasma proteins as DBP [39]. To explore the impacts of dialysis efficiency on serum protein profiles, Hallbauer et al. [40] conducted a 10-week cross-over study of high- and low-flux dialysis treatments with the identical membrane material in 16 ESRD patients. The serum protein profiles were not altered by the increased pore size of HD membrane in the high performance HD. They reasoned that there might be no significant permeability differences in the dialysis and the clearance of proteins by HD might be compensated by de novo production. Complimentary to the proteomic researches, the clinical landmark study of HEMO neither obtained significant beneficial effects on patients' survival by increasing higher dialysis dose or adopting the high-flux dialysis membranes [41]. It is important to perform long-term studies by using more advanced proteomic techniques to elucidate the effects of HD procedure on plasma proteome.

In conclusion, we observed that several altered plasma proteins in LHD survivors were related to signaling moieties of accelerated atherosclerosis, defective antioxidative activity, increased inflammation/infection, and organ dysfunction. Specifically, lower plasma DBP levels might be a predictor of cardiovascular mortality in HD patients. Further large-scale studies are warranted to consolidate this protein as a biomarker in prognoses, and to elucidate their roles in salient uremic milieu.

Supporting Information

Figure S1 Protein identification details of each spot. (PDF)

Data S1 The compressed file of all MS raw data for protein identification. (RAR)

Author Contributions

Conceived and designed the experiments: YPL, CWC, CHL. Performed the experiments: YPL, CYY, WCY. Analyzed the data: YPL, CYY, CCL, WCY. Conceived and designed the experiments: YPL, CWC, CHL. Performed the experiments: YPL, CYY, WCY. Analyzed the data: YPL, CYY, CCL, WCY. Contributed reagents/materials/analysis tools: YPL, CCL, CWC, CHL. Wrote the paper: YPL.

References

1. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, et al. (2011) US Renal Data System 2010 Annual Data Report. American journal of kidney diseases : the official journal of the National Kidney Foundation 57: A8, e1–e326.
2. McIntyre CW (2010) Recurrent circulatory stress: the dark side of dialysis. Seminars in dialysis 23: 449–451.
3. Himmelfarb J, Ikizler TA (2010) Hemodialysis. The New England journal of medicine 363: 1833–1845.
4. States DJ, Omenn GS, Blackwell TW, Ferrin D, Eng J, et al. (2006) Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nature biotechnology 24: 333–338.
21. Lee WM, Galbraith RM (1992) The extracellular actin-scavenger system and analysis by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clinica chimica acta; international journal of clinical chemistry 311: 95–107.

22. Dahl B, Schiedt FV, Ott P, Wians F, Lee WM, et al. (2003) Plasma concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. Critical care medicine 31: 152–156.

23. Schiedt FV, Bondeson S, Petersen I, Dalhoff K, Ott P, et al. (1996) Admission levels of serum Gc-globulin: predictive value in fulminant hepatic failure. Hepatology 23: 713–719.

24. Ishikawa Y, Ishii T, Akasaka Y, Masuda T, Strong JP, et al. (2001) Immunolocalization of apolipoproteins in aortic atherosclerosis in American youths and young adults: findings from the PDAY study. Atherosclerosis 138: 213–225.

25. Urbich C, Fritzenwanger M, Zeiher AM, Dimmeler S (2000) Laminar shear stress upregulates the complement-inhibitory protein clusterin: a novel potent defense mechanism against complement-induced endothelial cell activation. Circulation 101: 352–355.

26. Trougakos IP, Prevalakis I, Statathatos M, Chalikia A, Melidonis A, et al. (2002) Serum levels of the senescence biomarker clusterin/apolipoprotein J increase significantly in diabetes type II and during development of coronary heart disease or at myocardial infarction. Experimental gerontology 37: 1175–1187.

27. Petropoulou C, Trougakos IP, Keletas E, Toussaint O, Gemos ES (2003) Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS letters 585: 207–212.

28. Hatters DM, Wilson MR, Easterbrook-Smith SB, Howlett GJ (2002) Suppression of apolipoprotein C-II amyloid formation by the extracellular chaperone, clusterin. European journal of biochemistry/FEBS 269: 2789–2794.

29. Lin YP, Chen CH, Yu WC, Hsu TL, Ding PY, et al. (2002) Left ventricular mass and hemodynamic overload in normotensive hemodialysis patients. Kidney international 62: 1820–1828.

30. Qin X, Swertfeger DK, Zheng S, Hui DY, Tao P (1998) Apolipoprotein AI: a potent endogenous inhibitor of lipid oxidation. The American journal of physiology 274: H1836–1840.

31. Kronenberg F, Stuhlinger M, Trenkwalder E, Gethanfaj P, Schuering O, et al. (2000) Low apolipoprotein A-I plasma concentrations in men with coronary artery disease. Journal of the American College of Cardiology 36: 751–757.

32. Horl WH (2002) Hemodialysis membranes: interfacial, biocompatibility, and middle molecules. Journal of the American Society of Nephrology: JASN 13 Suppl 1: S62–71.

33. Jofre R, Rodriguez-Benitez P, Lopez-Gomez JM, Perez-Garcia R (2006) Inflammatory syndrome in patients on hemodialysis. Journal of the American Society of Nephrology 24: 268–274.

34. Sun Z, Yang P (2004) Role of imbalance between neutrophil elastase and alpha-1-antitrypsin in cancer development and progression. The lancet oncology 5: 182–190.

35. Borawski J, Naumnik B, Mysliwiec M (2003) Serum alpha1-antitrypsin but not alpha1-antichymotrypsin is associated with inflammation in the arterial wall in haemodialysis patients. Nephron failure 25: 589–593.

36. Lin YP, Chen CH, Yu WC, Hsu TL, Ding PY, et al. (2002) Left ventricular mass and hemodynamic overload in normotensive hemodialysis patients. Kidney international 62: 1820–1828.

37. Mosesson MW (2003) Fibrinogen gamma chain functions. Journal of thrombosis and haemostasis : JTH 1: 231–238.

38. Mancia-Garcia P, Garcia-Mendez A, Lopez-Ferre A, Macaya C, Nunez A, et al. (2004) Proteomic analysis of plasma from patients during an acute coronary syndrome. Journal of the American College of Cardiology 44: 1578–1583.

39. Dihazi H, Muller CA, Mattes H, Muller GA (2008) Proteomic analysis to better understand the pathogenetic mechanisms of diabetes type II: proteomic profiling of urine samples from diabetic and healthy subjects. Journal of proteome research 7: 3426–3436.

40. Horl WH (2002) Hemodialysis membranes: interfacial, biocompatibility, and middle molecules. Journal of the American Society of Nephrology: JASN 13 Suppl 1: S62–71.

41. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, et al. (2002) Effect of oral vitamin C supplementation in hemodialysis patients: a proteomic analysis. Proteomics 6: 993–1000.

42. Gotch FA (2000) Kt/V is the best dialysis dose parameter. Blood Purif 18: 276–285.

43. Thongboonkerd V, Chiangjong W, Mares J, Sulc J, Mares M, et al. (2009) Interleukin-6 levels in hemodialysis patients with and without low-grade inflammation. Renal failure 31: 95–107.

44. Petropoulou C, Trougakos IP, Keletas E, Toussaint O, Gemos ES (2003) Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS letters 585: 207–212.